Development of radioligands for the imaging of α7 nicotinic acetylcholine receptors with positron emission tomography.
Molecular imaging of brain structures by highly sensitive non-invasive techniques offers unique possibilities in the understanding of physiological and pathological processes in the central nervous system. In particular, the quantitative analysis by positron emission tomography (PET) of α7 nicotinic acetylcholine receptors (α7 nAChR), which are involved in different signalling pathways in the brain, is assumed to provide important information on the relation between receptor dysfunction and the pathogeneses of neuropsychiatric brain diseases, but the applicability of this imaging approach is still hampered due to insufficient imaging agents. This paper presents the recent efforts made to develop PET radiotracers targeting α7 nAChR as well as the current state of the evaluation of the most promising radiolabelled compounds in animal models and humans.
Division of Neuroradiopharmaceuticals, Institute of Radiopharmacy, Helmholtz-Zentrum Dresden - Rossendorf, Research Site Leipzig, 04318 Leipzig, Germany. p.brust@hzdr.de
Peter
P
Brust
Dan
D
Peters
Winnie
W
Deuther-Conrad
D000818:Animals; D001921:Brain / Q000000981:diagnostic imaging / Q000502:physiology / Q000503:physiopathology; D015195:Drug Design; D006801:Humans; D008024:Ligands; D057054:Molecular Imaging / Q000379:methods; D049268:Positron-Emission Tomography / Q000379:methods*; D019275:Radiopharmaceuticals; D011978:Receptors, Nicotinic / Q000378:metabolism*; D015398:Signal Transduction; D064569:alpha7 Nicotinic Acetylcholine Receptor
C579167:Chrna7 protein, human; D008024:Ligands; D019275:Radiopharmaceuticals; D011978:Receptors, Nicotinic; D064569:alpha7 Nicotinic Acetylcholine Receptor